NASDAQ:CRBP

Corbus Pharmaceuticals Stock Forecast, Price & News

$1.80
+0.05 (+2.86 %)
(As of 04/13/2021 04:00 PM ET)
Add
Compare
Today's Range
$1.74
Now: $1.80
$1.81
50-Day Range
$1.80
MA: $2.13
$2.92
52-Week Range
$0.91
Now: $1.80
$9.78
Volume91,442 shs
Average Volume13.63 million shs
Market Capitalization$225.06 million
P/E RatioN/A
Dividend YieldN/A
Beta2.14
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid drug that is in Phase III clinical trials for the treatment of systemic sclerosis and dermatomyositis, and in Phase IIb clinical trials to treat systemic lupus erythematosus and cystic fibrosis. The company is also developing CRB-4001, a peripherally-restricted CB1 inverse agonist, for nonalcoholic steatohepatitis and other fibrotic diseases. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, which includes the Jenrin library of approximately 600 compounds and multiple issued and pending patent filings; and strategic collaboration with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of lenabasum in Japan. The company was founded in 2009 and is based in Norwood, Massachusetts.
Corbus Pharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CRBP
CUSIPN/A
Phone617-963-0100
Employees141
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$36.14 million
Book Value$0.10 per share

Profitability

Net Income$-71,450,000.00
Net Margins-2,208.06%

Miscellaneous

Market Cap$225.06 million
Next Earnings Date5/10/2021 (Estimated)
OptionableOptionable

Headlines

Recap: Corbus Pharmaceuticals Q4 Earnings
March 15, 2021 |  finance.yahoo.com
Earnings Previews: Corbus Pharmaceuticals, Yalla
March 11, 2021 |  247wallst.com
CRBP Feb 2021 2.000 call
January 24, 2021 |  uk.finance.yahoo.com
CRBP Feb 2021 1.000 call
January 23, 2021 |  uk.finance.yahoo.com
CRBP Feb 2021 0.500 call
January 23, 2021 |  uk.finance.yahoo.com
CRBP Feb 2021 1.500 call
January 21, 2021 |  uk.finance.yahoo.com
The Little-Known Tech That Could Transform Healthcare
January 19, 2021 |  marketwatch.com
See More Headlines

MarketRank

Overall MarketRank

1.70 out of 5 stars

Medical Sector

275th out of 2,016 stocks

Pharmaceutical Preparations Industry

119th out of 771 stocks

Analyst Opinion: 3.2Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
$1.80
+0.05 (+2.86 %)
(As of 04/13/2021 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CRBP News and Ratings via Email

Sign-up to receive the latest news and ratings for CRBP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Corbus Pharmaceuticals (NASDAQ:CRBP) Frequently Asked Questions

Is Corbus Pharmaceuticals a buy right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corbus Pharmaceuticals in the last twelve months. There are currently 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Corbus Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CRBP, but not buy additional shares or sell existing shares.
View analyst ratings for Corbus Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Corbus Pharmaceuticals?

Wall Street analysts have given Corbus Pharmaceuticals a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Corbus Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Corbus Pharmaceuticals?

Corbus Pharmaceuticals saw a drop in short interest in February. As of February 26th, there was short interest totaling 13,580,000 shares, a drop of 38.7% from the February 11th total of 22,140,000 shares. Based on an average daily trading volume, of 14,750,000 shares, the short-interest ratio is currently 0.9 days.
View Corbus Pharmaceuticals' Short Interest
.

When is Corbus Pharmaceuticals' next earnings date?

Corbus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, May 10th 2021.
View our earnings forecast for Corbus Pharmaceuticals
.

How were Corbus Pharmaceuticals' earnings last quarter?

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) released its quarterly earnings results on Sunday, March, 14th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.25) by $0.15. The biopharmaceutical company earned $0.66 million during the quarter, compared to analysts' expectations of $1.24 million. Corbus Pharmaceuticals had a negative net margin of 2,208.06% and a negative trailing twelve-month return on equity of 485.45%.
View Corbus Pharmaceuticals' earnings history
.

How has Corbus Pharmaceuticals' stock price been impacted by COVID-19?

Corbus Pharmaceuticals' stock was trading at $4.12 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CRBP stock has decreased by 56.2% and is now trading at $1.8050.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for CRBP?

8 equities research analysts have issued 12-month price targets for Corbus Pharmaceuticals' shares. Their forecasts range from $2.50 to $32.00. On average, they anticipate Corbus Pharmaceuticals' share price to reach $15.69 in the next twelve months. This suggests a possible upside of 769.1% from the stock's current price.
View analysts' price targets for Corbus Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Corbus Pharmaceuticals' key executives?

Corbus Pharmaceuticals' management team includes the following people:
  • Dr. Yuval Cohen, CEO & Director (Age 46, Pay $810.55k)
  • Mr. Sean F. Moran CPA, M.B.A., CPA, MBA, Chief Financial Officer (Age 63, Pay $520k)
  • Dr. Barbara White, Head of Research & Chief Medical Officer (Age 71, Pay $570.7k)
  • Ted Jenkins, Sr. Director of Investor Relations & Corp. Communications
  • Dr. Mark A. Tepper, Co-Founder & Consultant (Age 64)
  • Scott Constantine, Sr. Director & Head of Clinical Operations
  • Mr. Craig Stuart Millian M.B.A., Chief Commercial Officer (Age 53)
  • Sergei Atamas, Exec. Director of Research

Who are some of Corbus Pharmaceuticals' key competitors?

What other stocks do shareholders of Corbus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corbus Pharmaceuticals investors own include Visa (V), HP (HPQ), Fortive (FTV), Lowe's Companies (LOW), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Matinas BioPharma (MTNB), (CGC), Inovio Pharmaceuticals (INO) and KushCo (KSHB).

What is Corbus Pharmaceuticals' stock symbol?

Corbus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRBP."

How do I buy shares of Corbus Pharmaceuticals?

Shares of CRBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Corbus Pharmaceuticals' stock price today?

One share of CRBP stock can currently be purchased for approximately $1.81.

How much money does Corbus Pharmaceuticals make?

Corbus Pharmaceuticals has a market capitalization of $225.68 million and generates $36.14 million in revenue each year. The biopharmaceutical company earns $-71,450,000.00 in net income (profit) each year or ($1.12) on an earnings per share basis.

How many employees does Corbus Pharmaceuticals have?

Corbus Pharmaceuticals employs 141 workers across the globe.

What is Corbus Pharmaceuticals' official website?

The official website for Corbus Pharmaceuticals is www.corbuspharma.com.

Where are Corbus Pharmaceuticals' headquarters?

Corbus Pharmaceuticals is headquartered at 500 River Ridge Drive, Norwood MA, 02062.

How can I contact Corbus Pharmaceuticals?

Corbus Pharmaceuticals' mailing address is 500 River Ridge Drive, Norwood MA, 02062. The biopharmaceutical company can be reached via phone at 617-963-0100 or via email at [email protected]


This page was last updated on 4/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.